Beta-amyloid PET/CT imaging for Alzheimer's diseaseIdentify, evaluate, and quantify
Several ground-breaking immunotherapy treatments have recently emerged that work to reduce beta-amyloid plaques that form in the brain and slow down cognitive decline in the early stages of Alzheimer's disease (AD). To qualify for these treatments, the presence of beta-amyloid plaque must be confirmed through diagnostic testing. Beta-amyloid PET/CT imaging plays a critical role in the AD care pathway, as it is one of the only modalities available to evaluate beta-amyloid plaque burden.
See our complete molecular imaging portfolio
Did this information help you?
1
Data on file.
2
Alzheimer's Association. FOR HEALTHCARE PROFESSIONALS. Frequently asked questions about beta-amyloid imaging. Available at https://www.alz.org/media/documents/health-care-pros-faqs-beta-amyloid-imaging.pdf. Accessed October 2023.
The products and features mentioned herein are not commercially available in all countries. Future availability cannot be guaranteed.